Tandem Diabetes Care, Inc. Stock price

Equities

TNDM

US8753722037

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-02-21 pm EST 5-day change 1st Jan Change
22.55 USD -4.29% Intraday chart for Tandem Diabetes Care, Inc. -8.15% -23.77%
Sales 2023 * 763M Sales 2024 * 842M Capitalization 1.54B
Net income 2023 * -210M Net income 2024 * -85M EV / Sales 2023 * 1.84 x
Net cash position 2023 * 130M Net cash position 2024 * 116M EV / Sales 2024 * 1.69 x
P/E ratio 2023 *
-6.97 x
P/E ratio 2024 *
-17.2 x
Employees 2,600
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.37%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.29%
1 week-8.15%
Current month-1.10%
1 month-8.89%
3 months+22.42%
6 months-22.69%
Current year-23.77%
More quotes
1 week
22.03
Extreme 22.03
25.77
1 month
21.85
Extreme 21.85
25.77
Current year
21.85
Extreme 21.85
30.18
1 year
13.82
Extreme 13.82
44.85
3 years
13.82
Extreme 13.82
155.86
5 years
13.82
Extreme 13.82
155.86
10 years
2.14
Extreme 2.14
269.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 13-02-28
Director of Finance/CFO 51 13-08-31
Compliance Officer 58 21-12-31
Members of the board TitleAgeSince
Chairman 64 19-01-02
Director/Board Member 64 13-06-30
Director/Board Member 71 07-08-31
More insiders
Date Price Change Volume
24-02-21 22.55 -4.29% 2,287,204
24-02-20 23.56 -3.52% 1,545,486
24-02-16 24.42 +0.54% 1,295,621
24-02-15 24.29 -1.06% 1,812,151
24-02-14 24.55 0.00% 1,087,009

Delayed Quote Nasdaq, February 21, 2024 at 04:00 pm EST

More quotes
Tandem Diabetes Care, Inc. is a medical device company. The Company is focused on the design, development, and commercialization of technology solutions for people living with diabetes. It manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. Its manufacturing, sales, and support activities principally focus on its flagship pump platform, the t:slim X2, and its complementary product offerings. Its t:slim X2 is based on the Company's technology platform and is the smallest durable insulin pump available in the United States. The Company has commercially offered two different automated insulin dosing (AID) algorithms on t:slim X2, including Control-IQ technology, which is an advanced hybrid-closed loop feature, designed to help increase a user's time in their targeted glycemic range. It was cleared by the Food and Drug Administration (FDA) to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
22.55 USD
Average target price
32.8 USD
Spread / Average Target
+45.45%
Consensus
  1. Stock
  2. Equities
  3. Stock Tandem Diabetes Care, Inc. - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer